ALK | Allergy solutions for life

Allergy solutions for life

Take back control

More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing.


  • Post date
    ALK and Grandpharma team up to market the first adrenaline autoinjector in China
  • Post date
    New, large, ‘real-world evidence’ study by ALK of AIT’s long-term effects on allergy and asthma presented at EAACI Congress
  • Post date
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    Three-month interim report (Q1) 2021
  • Post date
    Release date of three-month interim report (Q1) 2021 for ALK and audio cast
  • Post date
    ALK gains paediatric approval for its ragweed SLIT-tablet in the USA
  • Post date
    Grant of share options and performance shares to members of the Board of Management and key employees
  • Post date
    Annual General Meeting in ALK-Abelló A/S held on 18 March 2021
  • Post date
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

ALK supports eSOSA 2021

The SOSA programme includes the most recent updates in the field of specific allergy. The scientific programme for SOSA is developed by a pre-eminent International Scientific Committee and involves a faculty of around 35 distinguished speakers from the allergy scientific community. In 2021, to adapt to the COVID-19 limitations, SOSA will be held as a virtual event: eSOSA 2021.
Strategy update: Focus areas during 2021-23
Having made the necessary, significant investments to transform ALK, we are now entering the next phase of the company’s development, where we must carefully work to sustain long-term growth, while also returning ALK to profitability.
ALK rewards excellence in allergy
The Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy.

Seasonal allergy symptoms can be confused with COVID-19

Therefore allergy symptoms should be kept under the best possible control. Watch Dr Glenis Scadding's expert advise in respect of seasonal allergies and COVID-19.


ALK in brief

Allergy at a glance
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Our solutions
By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.
Our heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
Our responsibility
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.